Pharmaceuticals 2010, 3(2), 406-418; doi:10.3390/ph3020406

Deregulation of Interferon Signaling in Malignant Cells

,  and * email
Received: 10 December 2009; in revised form: 28 January 2010 / Accepted: 1 February 2010 / Published: 4 February 2010
(This article belongs to the Special Issue Interferons)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Interferons (IFNs) are a family of cytokines with potent antiproliferative, antiviral, and immunomodulatory properties. Much has been learned about IFNs and IFN-activated signaling cascades over the last 50 years. Due to their potent antitumor effects in vitro and in vivo, recombinant IFNs have been used extensively over the years, alone or in combination with other drugs, for the treatment of various malignancies. This review summarizes the current knowledge on IFN signaling components and pathways that are deregulated in human malignancies. The relevance of deregulation of IFN signaling pathways in defective innate immune surveillance and tumorigenesis are discussed.
Keywords: interferon; signaling pathways; cancer
PDF Full-text Download PDF Full-Text [1015 KB, uploaded 4 February 2010 11:53 CET]

Export to BibTeX |

MDPI and ACS Style

Katsoulidis, E.; Kaur, S.; Platanias, L.C. Deregulation of Interferon Signaling in Malignant Cells. Pharmaceuticals 2010, 3, 406-418.

AMA Style

Katsoulidis E, Kaur S, Platanias LC. Deregulation of Interferon Signaling in Malignant Cells. Pharmaceuticals. 2010; 3(2):406-418.

Chicago/Turabian Style

Katsoulidis, Efstratios; Kaur, Surinder; Platanias, Leonidas C. 2010. "Deregulation of Interferon Signaling in Malignant Cells." Pharmaceuticals 3, no. 2: 406-418.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert